Nothing Special   »   [go: up one dir, main page]

AR030432A1 - Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. - Google Patents

Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.

Info

Publication number
AR030432A1
AR030432A1 ARP010103092A ARP010103092A AR030432A1 AR 030432 A1 AR030432 A1 AR 030432A1 AR P010103092 A ARP010103092 A AR P010103092A AR P010103092 A ARP010103092 A AR P010103092A AR 030432 A1 AR030432 A1 AR 030432A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
defined above
represents hydrogen
hydrogen
Prior art date
Application number
ARP010103092A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR030432A1 publication Critical patent/AR030432A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El uso de derivados de quinazolina de formula (1) o una sal, éster o amida del mismo; en la cual X es O, o S, S(O) o S(O)2, o NR6 donde R6 es hidrogeno o alquilo C1-6; R5 es un anillo heteroaromático de 5 miembros opcionalmente sustituido, R1, R2, R3, R4 están independientemente seleccionados entre halo, ciano, nitro, trifluormetilo, alquilo C1-3, NR7R8 (donde R7 y R8 que pueden ser iguales o diferentes, representan cada uno hidrogeno o alquilo C1-3), o -X1R9 (donde X1 representa un enlace directo, -O-, -CH2-, -OCO-, carbonilo, -S-, -SO-, -SO2-, -NR10CO-, -CONR11-, -SO2NR12-, -NR13SO2-, o NR14 - (donde R10, R11, R12, R13 y R14 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3), y R9 está seleccionado entre uno de los siguientes grupos: 1) hidrogeno o alquilo C1-5 que puede estar no sustituido o puede estar sustituido con uno o más grupos seleccionados de hidroxi, fluor o amino, 2) alquilo C1-5X2COR15 (donde X2 representa -O- o -NR16- (en el cual R15 representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3 y R16 representa alquilo C1-3, -NR17R18 o -OR19 (donde R17, R18 y R19, que pueden ser iguales o diferentes, representan cada uno hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3)); 3) alquilo C1-5X3R20 (donde X3 representa -O-, -S-, -SO-, -SO2-, -OCO-, -NR21CO-, -CONR22-, -SO2NR23-, -NR24SO2- o -NR25- (donde R21, R22, R23, R24 y R25 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R20 representa hidrogeno, alquilo C1-3, ciclopentilo, ciclohexilo o un grupo heterocíclico saturado de 5-6 miembros con 1-2 heteroátomos, seleccionados independientemente de O, S y N, donde el grupo alquilo C1-3 puede ser portador de 1 o 2 sustituyentes seleccionados de oxo, hidroxi, halogeno y alcoxi C1-4 y donde el grupo cíclico puede ser portador de uno o dos sustituyentes seleccionados de oxo, hidroxi, halogeno, alquilo C1-4, hidroxialquilo C1-4, y alcoxi C1-4; 4) alquilo C1-5 X4 alquilo C1-5 X5R26 (donde X4 y X5, que pueden ser iguales o diferentes, son cada uno -O-, -S-, -SO-, -SO2-, -NR27CO-, -CONR28-, -SO2NR29-, -NR30SO2- o -NR31- (donde R27, R28, R29, R30 y R31 cada uno independientemente representa hidrogeno, alquilo C1-3 y alcoxi C1-3 alquilo C2-3) y R26 representa hidrogeno o alquilo C1-3); 5) R32 (donde R32 es un grupo heterocíclilo saturado de 5-6 miembros (ligado a través de carbono o nitrogeno) con 1-2 heteroátomos, seleccionados independientemente de O, S y N, donde el grupo heterocíclico puede ser portador de uno o dos sustituyentes seleccionados de oxo, hidroxi, halogeno, alquilo C1-4, hidroxialquilo C1-4, alcoxi C1-4, alcoxi C1-4 alquilo C1-4 y alquilsulfonil C1-4 alquilo C1-4); 6) alquilo C1-5 R32 (donde R32 es tal como se ha definido anteriormente); 7) alquenilo C2-5 R32 (donde R32 es tal como se ha definido anteriormente); 8) alquinilo C2-5R32 (donde R32 es tal como se ha definido anteriormente); 9) R33 (donde R33 representa un grupo piridona, fenilo o un grupo heterocíclico aromático de 5-6 miembros (ligado a través de carbono o nitrogeno) con 1-3 heterátomos seleccionados de O, N y S, donde el grupo piridona, fenilo o heterocíclico aromático puede ser portador de hasta 5 sustituyentes sobre un átomo de carbono asequible, seleccionados de hidroxi, halogeno, amino, alquilo C1-4, alcoxi C1-4, hidroxialquilo C1-4, aminoalquilo C1-4, alquilamino C1-4, hidroxialcoxi C1-4, carboxi, trifluormetilo, ciano, -CONR34R35 y -NR36COR37 (donde R34, R35,R36 y R37, que pueden ser iguales o diferentes, representa cada uno hidrogeno, alquilo C1-4 o alcoxi C1-3 alquilo C2-3)); 10) alquilo C1-5R33 (donde R33 es tal como se ha definido anteriormente); 11) alquenilo C2-5 R33(donde R33 es tal como se ha definido anteriormente); 12) alquinilo C2-5R33 (donde R33 es tal como se ha definido anteriormente); 13) alquilo C1-5X6R33 (donde X6 representa -O-, -S-, -SO2-, -NR38CO-, -CONR39-, -SO2NR40-, -NR41SO2- o -NR42- (donde R38, R39, R40, R41 y R42 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 14) alquenilo C2-5X7R33 (donde X7 representa -O-, -S-, -SO-, -SO2-, -NR43CO-, -CONR44-, -SO2NR45, -NR46SO2-, o -NR47- (donde R43, R44, R45, R46 y R47 cada uno independientemente representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 15) alquinilo C2-5X8R33 (donde X8 representa -O-, -S-, -SO-, -SO2-, -NR48CO-, -CONR49-, -SO2NR50-, -NR51SO2- o -NR52- (donde R48, R49, R50, R51 y R52 cada uno independientemente representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 16) alquilo C1-3X9 alquilo C1-3R33 (donde X9 representa -O-, -S-, -SO-, -SO2-, -NR53CO-, -CONR54-, -SO2NR55-, -NR56SO2- o -NR57- (donde R53, R54, R55, R56 y R57 cada uno de los cuales representa independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente) y 17) alquilo C1-3X9 alquilo C1-3R32 (donde X9 y R28 son tal como se han definido anteriormente); que se usa en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmacéutica.
ARP010103092A 2000-06-28 2001-06-28 Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. AR030432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00401842 2000-06-28

Publications (1)

Publication Number Publication Date
AR030432A1 true AR030432A1 (es) 2003-08-20

Family

ID=8173742

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103092A AR030432A1 (es) 2000-06-28 2001-06-28 Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.

Country Status (27)

Country Link
US (2) US6919338B2 (es)
EP (1) EP1299381B1 (es)
JP (1) JP2004501914A (es)
KR (1) KR20030014411A (es)
CN (1) CN1267431C (es)
AR (1) AR030432A1 (es)
AT (1) ATE394102T1 (es)
AU (1) AU2001266505A1 (es)
BG (1) BG107376A (es)
BR (1) BR0111754A (es)
CA (1) CA2412592A1 (es)
CZ (1) CZ20024120A3 (es)
DE (1) DE60133897D1 (es)
EE (1) EE200200715A (es)
ES (1) ES2305081T3 (es)
HK (1) HK1053124A1 (es)
HU (1) HUP0301236A2 (es)
IL (1) IL153246A0 (es)
IS (1) IS6656A (es)
MX (1) MXPA02011974A (es)
NO (1) NO20026010L (es)
NZ (1) NZ522696A (es)
PL (1) PL360439A1 (es)
RU (1) RU2283311C2 (es)
SK (1) SK18102002A3 (es)
WO (1) WO2002000649A1 (es)
ZA (1) ZA200209412B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302172A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100909665B1 (ko) * 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
RU2323215C2 (ru) 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
ATE489384T1 (de) * 2002-05-06 2010-12-15 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
EP1532145B1 (en) 2002-08-02 2006-09-13 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
WO2004058781A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CN101074227B (zh) * 2002-12-24 2010-09-29 阿斯利康(瑞典)有限公司 膦酰氧基喹唑啉衍生物及其药物用途
EP1575946A1 (en) * 2002-12-24 2005-09-21 AstraZeneca AB Quinazoline compounds
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1613619B1 (en) * 2003-04-16 2008-03-26 AstraZeneca AB Quinazoline derivatives for treatment of cancer
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
DE602004022318D1 (de) * 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
EP1678149A2 (en) * 2003-10-31 2006-07-12 Neurogen Corporation 4-amino(aza)quinoline derivatives as capsaicin receptor agonists
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US8119684B2 (en) * 2003-12-30 2012-02-21 Dana-Farber Cancer Institute, Inc. Thiophene derivatives for up-regulating HLA-DM activity
US7687502B2 (en) * 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
US20090036485A1 (en) * 2004-10-12 2009-02-05 Frederic Henri Jung Quinoline derivatives
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006311830B2 (en) * 2005-11-03 2013-03-14 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8236823B2 (en) * 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
WO2008077086A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2680029A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2679884A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
MX2009010517A (es) 2007-04-05 2009-10-19 Amgen Inc Moduladores de cinasa aurora y metodos de uso.
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5572087B2 (ja) * 2007-05-02 2014-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
JP5389786B2 (ja) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
WO2008137619A2 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
ES2395581T3 (es) * 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
EP2170842A1 (en) * 2007-06-21 2010-04-07 Irm, Llc Protein kinase inhibitors and methods for using thereof
EP2176261B1 (en) * 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US8404694B2 (en) * 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
EP2323622A1 (en) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
ES2489040T3 (es) 2008-12-03 2014-09-01 The Scripps Research Institute Cultivos de células madre
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
AU2010204619B2 (en) 2009-01-16 2016-08-11 Exelixis, Inc. Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
BRPI1008325A2 (pt) * 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012066578A2 (en) * 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
CN103788085B (zh) * 2012-10-31 2016-09-07 复旦大学 2-(喹唑啉-4-氨基)-5-噻唑甲酰胺类衍生物及其生物药物用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN105555315B (zh) 2013-09-16 2019-05-07 阿斯利康(瑞典)有限公司 治疗性聚合物纳米颗粒及其制备和使用方法
CN108473435A (zh) 2015-10-05 2018-08-31 纽约市哥伦比亚大学理事会 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP4025565A1 (en) * 2019-09-06 2022-07-13 Inflazome Limited Nlrp3 inhibitors
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 一种氨基噻唑类化合物的合成方法
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
CN115557601B (zh) * 2022-11-08 2024-11-08 成都理工大学 生物质微球及其制备方法与应用、生物反应器、地下井
WO2024184550A1 (en) * 2023-03-09 2024-09-12 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2241324T3 (es) * 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
US20060046987A1 (en) 2006-03-02
ZA200209412B (en) 2004-02-19
CA2412592A1 (en) 2002-01-03
KR20030014411A (ko) 2003-02-17
CN1267431C (zh) 2006-08-02
HK1053124A1 (en) 2003-10-10
PL360439A1 (en) 2004-09-06
RU2283311C2 (ru) 2006-09-10
CZ20024120A3 (cs) 2003-03-12
BR0111754A (pt) 2003-04-29
NO20026010D0 (no) 2002-12-13
MXPA02011974A (es) 2004-09-06
EP1299381A1 (en) 2003-04-09
BG107376A (bg) 2003-09-30
ES2305081T3 (es) 2008-11-01
WO2002000649A9 (en) 2007-09-20
IS6656A (is) 2002-12-17
NO20026010L (no) 2002-12-13
ATE394102T1 (de) 2008-05-15
EP1299381B1 (en) 2008-05-07
SK18102002A3 (sk) 2003-07-01
DE60133897D1 (de) 2008-06-19
AU2001266505A1 (en) 2002-01-08
IL153246A0 (en) 2003-07-06
CN1496364A (zh) 2004-05-12
WO2002000649A1 (en) 2002-01-03
JP2004501914A (ja) 2004-01-22
EE200200715A (et) 2004-08-16
HUP0301236A2 (hu) 2003-10-28
NZ522696A (en) 2004-08-27
US6919338B2 (en) 2005-07-19
US20030187002A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
AR038476A1 (es) Derivados de quinazolina
AR037881A1 (es) Uso de derivados de oxindol
AR045691A1 (es) Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR038052A1 (es) Derivados de quinazolina como inhibidores de auroraquinasas
ATE330959T1 (de) Allosterische adenosin-rezeptor-modulatore
AR025735A1 (es) Compuestos terapeuticos
HUP0001446A2 (hu) HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
CR8859A (es) Derivados de piridina
HUP0300894A2 (hu) Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE0102438D0 (sv) New compounds
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
CY1112178T1 (el) Παραγωγα πιπεραζινης και χρηση αυτων ως θεραπευτικων παραγοντων
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
EE200100491A (et) Tetrahüdropüraani derivaadid, nende saamine ja kasutamine ravimainetena ning neid sisaldav farmatseutiline kompositsioon
PE20020759A1 (es) Derivados de bencilamina con base prolina como inhibidores de trombina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal